Frontiers in Psychiatry
November 13, 2023
Tor-Morten Kvam, Malin V. Uthaug, Kristoffer A A Andersen et al.
21 citations
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders and substance use disorders. However, knowledge about the epidemiology of classic psychedelics in the Nordic countries is limited. Methods We recruited adult, Norwegian participants who have had...
Highlights in Science Engineering and Technology
August 29, 2023
Xuehan Du
1 citation
Psilocybin, a psychoactive alkaloid with hallucinogenic properties, exists in a variety of hallucinogenic mushrooms. As a study tool to imitate psychosis, psilocybin has aroused a lot of interest in the biological community due to its various possible therapeutic benefits. It is also a very popular and widely misused natural hallucinogens with distinct metabolism pathways and toxicity. In this...
Journal of Psychoactive Drugs
August 24, 2023
Stanley Wong, An Yi Yu, Nicholas Fabiano et al.
11 citations
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...
Canadian journal of health history = Revue canadienne d'histoire de la sante
April 1, 2023
Andrew Jones
2 citations
In 1962, Ontario's Addiction Research Foundation launched the first double-blind randomized controlled trial of LSD therapy as a treatment for alcoholism. The study, which found that LSD was not effective, was heavily criticized by other therapists working with the drug. These critics argued that the Toronto researchers who carried out the study were biased against LSD and used an...
European Psychiatry
March 1, 2023
R. Sousa, Luís Costa, J. Brás et al.
Introduction Substance use disorders(SUDs) are a major health concern and current treatment interventions have proven only limited success. Despite increasing effectiveness, still about 50–60% relapse within 6–12 months after treatment [Cornelius et al ., Addict Behav. 2003;28 381-386]. SUDs are defined as chronic disorders of brain reward system, motivation, and memory processes that have gone...
Alcoholism & Drug Abuse Weekly
October 14, 2022
Alison Knopf
The beneficial effects of psilocybin‐assisted psychotherapy on alcohol use disorder (AUD) are significant, based on a study published in JAMA Psychiatry last month. In general, psychedelic medications have been a focus of research, but less is known about psilocybin, and it has been 40 years since the studies with lysergic acid diethylamide (LSD) provided double the remissions as comparison...
Experimental and Clinical Psychopharmacology
September 1, 2022
Julie A E Christensen, David C. Fipps, J Michael Bostwick
4 citations
Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...
Psychiatric Annals
September 1, 2022
Brian S. Barnett, Jeremy Weleff
6 citations
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...
Molecules
April 13, 2022
Henry Lowe, Ngeh J. Toyang, Blair Steele et al.
53 citations
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...
Journal of the Neurological Sciences
March 15, 2022
David E Smith
In 1965, I was training in clinical toxicology in the pharmacology department of the University of California San Francisco (UCSF) and living in the Haight Ashbury. I studied various psychedelics, including LSD, mescaline, and ibogaine, in human and animal models. The psychedelics were then being used as a therapeutic drug in clinical settings and researched as a potential antipersonnel agent...